ra-iwinyro.blogspot.com
Life sciences and technology investo rSafeguard (NYSE:SFE) said the gain and an increase in equity will be recognized in the current quarterd ending June 30. A privat placement with reduced Safeguard’s shard in Clarient (NASDAQ:CLRT) from aboutr 50 percent to about 47 Safeguard President and CEOPeter J. Boni said the deal “noy only strengthened our balance sheer andfinancial flexibility, but the value of Safeguard’sx ongoing stake in Clarient can now be more readily understooxd by the investment community.” Safeguard said the markeyt value of its remaining holdings is about $123 millionj as of Wednesday.
Clarient provides anatomic pathologt and molecular testing servicesto pathologists, oncologists and the pharmaceuticakl industry. It’s based in Alis o Viejo, Calif.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment